ClinicalTrials.Veeva

Menu

Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects

L

Ludwig Maximilian University of Munich

Status

Completed

Conditions

Schizophrenia

Treatments

Procedure: IBZM-SPECT (bolus and constant infusion paradigm)

Study type

Interventional

Funder types

Other

Identifiers

NCT00166322
EK076/03
DYN-SPECT-Pogarell

Details and patient eligibility

About

This study is an investigation of the dopaminergic neurotransmission in patients with schizophrenia, patients at risk for the development of schizophrenia, and healthy controls using an iodobenzamide-single photon emission computed tomography (IBZM-SPECT) imaging technique under amphetamine challenge.

Enrollment

35 patients

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Clinical diagnosis of schizophrenia (currently unmedicated)
  • Subjects at risk for the development of schizophrenia (prodromal symptoms)
  • Healthy subjects
  • Written informed consent

Exclusion criteria

  • Neurological or severe somatic disorders
  • Women during pregnancy or lactation
  • Occupational exposition to radiation > 15mSv
  • Medication known to interfere with IBZM
  • Contraindications for the use of amphetamine challenge

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems